Equities

Organovo Holdings Inc

Organovo Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.4964
  • Today's Change-0.011 / -2.09%
  • Shares traded90.48k
  • 1 Year change-66.91%
  • Beta0.6156
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast in USD

The one analyst offering a 12 month price target expects Organovo Holdings Inc share price to rise to 6.10 in the next year from the last price of 0.4964.
High1,128.8%6.10
Med1,128.8%6.10
Low1,128.8%6.10

Earnings history & estimates in USD

On Aug 05, 2024, Organovo Holdings Inc reported 1st quarter 2025 losses of -0.23 per share.
The next earnings announcement is expected on Nov 07, 2024.
Average growth rate+26.87%
Organovo Holdings Inc reported annual 2024 losses of -1.60 per share on May 31, 2024.
Average growth rate+6.99%
More ▼

Revenue history & estimates in USD

Organovo Holdings, Inc. had 1st quarter 2025 revenues of 25.00k. This missed the 30.00k estimate of the one analyst following the company.
Average growth rate+122.07%
Organovo Holdings, Inc. had revenues for the full year 2024 of 109.00k. Last year the company did not report any revenues.
Average growth rate-37.01%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.